Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DLBS-32
- Development stage
- Phase 2
- Lead developer
- Dexa Medica
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DLBS-32 is a bioactive fraction derived from the plant *Lagerstroemia speciosa* (commonly known as banaba). It has been investigated for its potential use in the management of type 2 diabetes mellitus. Clinical studies have focused on evaluating its efficacy and safety in improving glycemic control in patients with type 2 diabetes. The mechanism of action is believed to involve modulation of glucose metabolism, although specific molecular targets are not clearly defined in available clinical trial summaries. DLBS-32 is developed as a natural product-based intervention rather than a conventional pharmaceutical agent.
Beyond the preview
Go deeper on DLBS-32.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DLBS-32.